Nepafenac clinical trials
Also written Nevanac.
How each study uses nepafenac is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nepafenac studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Aug 2005 · NEVANAC · NDA 021862 (FDA, Drugs@FDA)
- European Union
- 11 Dec 2007 · Nevanac · EMEA/H/C/000818 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2009 (7)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 7 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 6 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 34
Alcon Research (10) · University Hospital of Patras (2) · Frank A. Bucci, Jr., M.D. (2) · Instituto de Oftalmología Fundación Conde de Valenciana (1) · Muhammad Aamir Latif (1) · Ankara Yildirim Beyazıt University (1) · Pomeranian Medical University Szczecin (1) · Indonesia University (1)
Often tested with
Tested in the same studies.
Ketorolac (10) · Bromfenac (8) · Diclofenac (3) · Ketorolac Tromethamine (3) · Lubricant (1) · Triamcinolone (1) · Indomethacin (1) · Difluprednate (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses nepafenac is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 47
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract SurgeryRecruitingNot applicableNemocnice KolínNCT07178639Written as Nepafenac 0.3% Oph SuspHow we know
- Comparison Between Low-Dose and High-Dose Nepafenac SodiumCompletedNot applicableMuhammad Aamir LatifNCT07749027Written as Nepafenac sodium (High-dose )How we know
- Perioperative Topical Nepafenac After Epiretinal Membrane SurgeryCompletedPhase 4Ankara Yildirim Beyazıt UniversityNCT07736690Written as Nepafenac 0.1% Ophthalmic SuspensionHow we know
- Efficacy of Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Cystoid Macular Edema Following Cataract PhacoemulsificationCompletedPhase 4Pomeranian Medical University SzczecinNCT07696104Written as Nepafenac 0.1% eyedropsHow we know
- A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum StenosisActive, not recruitingPhase 4Instituto de Oftalmología Fundación Conde de ValencianaNCT07372014Written as Nepafenac and lubricantHow we know
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative VitreoretinopathyCompletedPhase 4Indonesia UniversityNCT07162818Written as Nepafenac 0.1% eyedropsHow we know
- NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)CompletedPhase 2Jaeb Center for Health ResearchNCT01331005Written as nepafenac 0.1% dropsHow we know
- Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal PhotocoagulationTerminatedPhase 2Asociación para Evitar la Ceguera en MéxicoNCT00801905Written as NepafenacHow we know
- CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye DropsStatus unknownPhase 2L.V. Prasad Eye InstituteNCT04843839Written as Nepafenac 0.1% Oph SuspHow we know
- Clinical Endpoint Study of Nepafenac 0.3% Opthalmic SuspensionCompletedPhase 3Actavis Inc.NCT03499873Written as Nepafenac 0.3% Oph SuspHow we know
- Macular Edema Nepafenac vs. Difluprednate Uveitis TrialTerminatedPhase 4University of California, San FranciscoNCT01939691Written as NepafenacHow we know
- Post Intravitreal Injection Topical NSAID vs. PatchingStatus unknownPhase 4The New York Eye & Ear InfirmaryNCT03918590Written as nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)How we know
- Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical TrialCompletedPhase 4Silverstein Eye CentersNCT03886779Written as NepafenacHow we know
- Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus PlaceboCompletedNot applicableIntuor Technologies, Inc.NCT03025945Written as Nepafenac 0.3%How we know
- Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract SurgeryCompletedNot applicableMelissa ToyosNCT01847638Written as Ilevro (nepafenac 0.3%)How we know
- PGE2 Levels in Patient Treated With NSAIDsCompletedPhase 3University of TriesteNCT03597867Written as NevanacHow we know
- Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral IridotomyStatus unknownNot applicableSheba Medical CenterNCT02955641Written as Nepafenac 0.1%How we know
- Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal InjectionsCompletedNot applicableUniversity Hospital of PatrasNCT03406689Written as Nepafenac 0.1% Oph SuspHow we know
- Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular EdemaCompletedPhase 3Federal University of São PauloNCT00780780Written as Triamcinolone + NepafenacHow we know
- Dropless vs. Standard Drops Contralateral Eye StudyCompletedPhase 4Carolina Eyecare Physicians, LLCNCT02515045Written as IlevroHow we know
See all 47 studies that test nepafenac →
As the comparator · 2 — what is tested is compared with nepafenac
- Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%CompletedPhase 4Toyos ClinicNCT01310127Written as NepafenacHow we know
- Efficacy and Safety of PRO-155 Versus Nevanac in Post PhacoemulsificationCompletedPhase 2Laboratorios Sophia S.A de C.V.NCT01657266Written as NevanacHow we know
Codes
What other systems call nepafenac · ClinicalTrials.gg INT004269
- MeSH (NLM) C414203nepafenacConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0J9L7J6V8CNEPAFENACConfirmed FDA, NLM, Wikidata
- RxNorm 298665Confirmed FDA, Wikidata
- Wikidata Q684379nepafenacConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66228NepafenacOne source FDA
- DrugBank DB06802One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C414203 | nepafenac | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0J9L7J6V8C | NEPAFENAC | Confirmed FDA, NLM, Wikidata |
| RxNorm | 298665 | — | Confirmed FDA, Wikidata |
| Wikidata | Q684379 | nepafenac | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66228 | Nepafenac | One source FDA |
| DrugBank | DB06802 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.